Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma
Credit Suisse: Regeneron Now Worth $550/Share
Amgen gets cholesterol edge (Investor's Business Daily)
Related SNY
Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
CVS Says New Cholesterol Drug Types Could Be Costly
Amgen gets cholesterol edge (Investor's Business Daily)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters